A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have a Mutation of the PIK3CA Gene
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Alpelisib (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 29 May 2018 Planned End Date changed from 31 Dec 2018 to 25 Dec 2018.
- 06 Feb 2018 Planned End Date changed from 1 Jun 2018 to 31 Dec 2018.
- 06 Feb 2018 Planned primary completion date changed from 1 Jun 2018 to 31 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History